How wearables are battling workplace violence To view this email as a web page,
click here After COVID-19 spotlighted supply chain weaknesses, Biden unveils plan to resurrect U.S. drug manufacturing Vizient report expects patient volumes to fully rebound in 2022 after COVID-19 losses As COVID-19 exacerbates violence in the workplace, one health system is using discreet wearables to protect staff COVID-19 tracker: Study finds no additional benefit from vaccination among those previously infected LetsGetChecked hits unicorn status with $150M to grow at-home testing, telehealth services Boehringer Ingelheim taps into Lifebit's AI for global disease surveillance CMO Selkirk blueprints $90M factory to help bring injectable drug manufacturing stateside Featured Story | By Fraiser Kansteiner After shining a spotlight on America’s supply chains, including those for drugs and pharmaceutical ingredients, the Biden administration has revelations to share—and a sweeping strategy to boost domestic drug production. The plan includes a new public-private manufacturing consortium, investments in advanced production technologies and more. read more |
| |
|---|
|
| | Benefits of Decentralized Clinical Trials To execute decentralized research strategies, sponsors are turning to an integrated supply chain solution known as Direct-to-Patient Services. This service allows patients to participate in clinical trials from their homes by providing them with study drugs and care where they live. Learn more. |
Top Stories By Robert King A new report projects that patient volumes will surpass pre-pandemic levels in 2022 but emergency department visits are expected to face a prolonged decline. read more By Dave Muoio Bassett Healthcare Network will be the first system to deploy the Strongline Staff Safety System across its entire caregiver workforce. The deployment comes as healthcare executives, legislators and labor groups alike call for an increased focus on healthcare workers' safety. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner A study by the Cleveland Clinic showed that people who were infected with COVID-19 and later were vaccinated received no additional protection. Australia will not follow the lead of Canada, which is offering people a mix of adenovirus and mRNA vaccines. And more headlines. read more By Andrea Park The at-home diagnostics provider closed its high-flying series D with support from a handful of longtime backers that included Illumina Ventures, UnitedHealth’s Optum Ventures and golfer Rory McIlroy, through his own Symphony Ventures. read more By Conor Hale Boehringer Ingelheim's ambitious project with AI developer Lifebit aims to use natural language processing to help chart a course among new global outbreaks of infectious diseases. read more By Fraiser Kansteiner While Selkirk's 2018 launch predates COVID-19, the CMO is pitching itself as another champion in the quest to “onshore” drug manufacturing capabilities in the U.S. As part of that effort, the company unveiled a $90 million plant pegged to shore up local capacity for injectable drugs. read more | | Webinar: Accelerating NASH Clinical Trials Tuesday, June 15 | 10am ET / 7am PT Join industry leaders for a webinar dedicated to overcoming key challenges presented in NASH drug development. We’ll explore key considerations for liver biopsy collection and interpretation, emerging non-invasive biomarkers, and the connection between clinical practice and drug development. Register now. |
|
|
